GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline (GSK). GSK-923295... GSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors.
- Mechanism
- Curator reviewed
GSK-923295 is an inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E). CENP-E plays an essential role in chromosome movement during early cell division or mitosis and integrates mitotic spindle mechanics with regulators of the mitotic checkpoint regulating cell-cycle transition from metaphase to anaphase. Inhibition of CENP-E induces cell cycle arrest during cell duplication leading to subsequent apoptosis or cell death.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.Curator reviewed
- Code names
- GSK-923295
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with GSK-923295, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account